- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00550108
Management of Incidentally Discovered Pancreatic Cysts
23. juni 2008 opdateret af: Massachusetts General Hospital
A Prospective Study of the Management of Incidentally Discovered Pancreatic Cysts
The purpose of this study is to determine the natural history of pancreatic cysts and to determine if these cysts can be effectively treated with a less invasive therapy (ethanol injection vs periodic imaging) rather than surgical resection
Studieoversigt
Detaljeret beskrivelse
The appropriate management of patients with cystic lesions of the pancreas is controversial.
The identification of small asymptomatic pancreatic cysts is increasing due to an improvement in the quality of radiologic imaging and the frequency that imaging is obtained.
However, the natural history of these lesions is unknown1.
The current consensus guidelines established at the International Consensus Conference in Sendai, Japan in 2005 suggest that branch chain IPMNs and mucinous cystic neoplasms that cause no symptoms, measure <3cm, and have no nodules can be observed with periodic imaging.
However, the time course of these pre malignant mucinous lesions, intraductal papillary mucinous neoplasms (IPMN) or mucinous cystadenomas, from benign to malignant has not been determined.
Due to the unknown natural history, and diagnostic uncertainty, some authors have recommended routine resection2, 3. Resection, despite improvements in surgical outcomes after pancreatectomy at high volume centers, carries a mortality and morbidity of 1-6% and 35-51%, respectively4-6.
More recently studies are reporting a more selective approach to avoid the risk of operation in patients with benign lesions7.
Improved radiographic and endoscopic studies have been able to identify some lesions with increased malignant potential8, 9. Thus, most patients will undergo pancreas specific radiologic imaging and endoscopic ultrasound with cyst aspiration.
Since the natural history of cystic lesions is poorly understood no clear guidelines for surgical resection have been established.
Some of the cysts will grow over time, with an increase in the cumulative risk of malignancy.
Therefore, the therapeutic alternatives are to wait and watch for a change in the cyst morphology or to treat preemptively, which has been restricted to surgical resection.
Based on the pilot study performed by Dr. William Brugge, at Massachusetts General Hospital, ethanol lavage of pancreatic cysts is safe and will result in a decrease in cyst diameter in 61% of patients.
Additionally, if patients elect to not be treated preemptively it is unclear how to best follow these patients in terms of the type and the frequency of follow up studies.
Undersøgelsestype
Interventionel
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 90 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Cyst between 1-3cm
- No evidence of a mural nodule, solid component, or septations in the cyst
- For patients with multiple cysts, the largest will be evaluated
Exclusion Criteria:
- Any imaging or cytology concerning for malignancy
- Pancreatic Pseudocyst
- Gross Cyst >3cm as measured on MRCP
- Clinically active pancreatitis or serum amylase or lipase >3x upper limit of normal
- Coagulopathy (INR>1.5, PTT>100, Platelets<50K)
- Inability to tolerate conscious sedation and endoscopy
- Rated ASA IV or greater
- Prior EUS and aspiration of the pancreatic cyst
- Breast feeding
- Pregnancy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: A
Observation of pancreatic cysts
|
|
|
Eksperimentel: B
Ethanol lavage of pancreatic cysts
|
Ethanol lavage of pancreatic cysts.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule.
Tidsramme: 3 years
|
3 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)?
Tidsramme: 3 years
|
3 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Cristina R Ferrone, MD, Massachusetts General Hospital
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2007
Primær færdiggørelse (Forventet)
1. oktober 2012
Studieafslutning (Forventet)
1. oktober 2012
Datoer for studieregistrering
Først indsendt
24. oktober 2007
Først indsendt, der opfyldte QC-kriterier
24. oktober 2007
Først opslået (Skøn)
26. oktober 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
26. juni 2008
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. juni 2008
Sidst verificeret
1. juni 2008
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2007-P-000420
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .